62 views
– October marked a year since I started taking this medication. Tofersen is specifically targeted at a given mutation – the one I have. I haven’t seen any progression of the disease since October last year. Considering how it developed earlier, what happened to me, that I was losing strength in my legs, the ability to climb stairs, at the moment I believe that the disease has stopped – says Monika Partyka, a patient with ALS-SOD1, covered by the early access program for tofersen therapy, in an interview for Medexpress.